Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
NCT04668365 · Henan Cancer Hospital · PHASE2 · suspended · last registry update 2025-04-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Data in analysis” | – | Registry record, Henan Cancer Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BTK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-07Phase 3 first posted: Nurix Therapeutics, Inc., NX-5948 + Pirtobrutinib (NCT07516093)
- 2026-04-02Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT03220022)
- 2026-04-01Results posted on the registry: Matthew C. Baker, Zanubrutinib 80 MG (NCT04602598)
- 2026-03-25Results posted on the registry: BeiGene, Zanubrutinib (NCT05068440)
- 2026-03-17Results posted on the registry: Pharmacyclics LLC., Ibrutinib Oral Capsule + Placebo (NCT02947347)
- 2026-03-02Also stopped (terminated): H. Lee Moffitt Cancer Center and Research Institute, Pembrolizumab + Ibrutinib (NCT03514017)
- 2026-02-23Results posted on the registry: Principia Biopharma, a Sanofi Company, Rilzabrutinib + Placebo (NCT04562766)
- 2026-02-20Results posted on the registry: BeiGene, BGB-10188 + Zanubrutinib (NCT04282018)
- 2026-02-02Results posted on the registry: National Cancer Institute (NCI), Ibrutinib + Obinutuzumab (NCT03737981)
- 2026-01-30Phase 3 first posted: Guangzhou Lupeng Pharmaceutical Company LTD., Rocbrutinib + Ibrutinib (NCT07377578)
- 2026-01-27Results posted on the registry: Kerry Rogers, Bcl-2 Inhibitor GDC-0199 + Obinutuzumab (NCT02427451)
- 2026-01-15Phase 3 first posted: Newave Pharmaceutical Inc, Rocbrutinib + Pirtobrutinib (NCT07342478)
- 2026-01-07Phase 3 first posted: Alliance for Clinical Trials in Oncology, Zanubrutinib + Sonrotoclax (NCT07321652)
- 2025-12-23Phase 3 first posted: Zenas BioPharma (USA), LLC, Orelabrutinib + Placebo (NCT07299019)
- 2025-12-11Phase 3 first posted: BeOne Medicines, Sonrotoclax + Zanubrutinib (NCT07277231)
- 2025-11-14Results posted on the registry: Principia Biopharma, a Sanofi Company, Rilzabrutinib (NCT03395210)
- 2025-10-23Phase 3 first posted: SWOG Cancer Research Network, Cyclophosphamide + Doxorubicin Hydrochloride (NCT07220187)
- 2025-10-15Results posted on the registry: Acerta Pharma BV, acalabrutinib + rituximab (IV) (NCT02180711)
- 2025-10-14Phase 3 first posted: Sanofi, rilzabrutinib (NCT07216079)
- 2025-09-30Results posted on the registry: National Cancer Institute (NCI), Carmustine + Cyclophosphamide (NCT02443077)
- 2025-09-24Phase 3 first posted: Sanofi, Rilzabrutinib + Placebo (NCT07190196)
- 2025-09-22Phase 3 first posted: Huashan Hospital, Teniposide + Orelabrutinib (NCT07185373)
- 2025-09-18Results posted on the registry: Mayo Clinic, Ibrutinib + Ixazomib Citrate (NCT03506373)
- 2025-08-14Results posted on the registry: Pfizer, PF-06651600 + Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine (NCT04006457)
- 2025-08-12Results posted on the registry: Dana-Farber Cancer Institute, Venetoclax + Obinutuzumab (NCT03580928)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision